source
- BMS trial sees patient death, analysts say drug mechanism still viableBristol Myers Squibb is running a phase 3 study of an LPA1 inhibitor, admilparant, for idiopathic and progressive pulmonary fibrosis. A patient death was reported after the trial was amended to inc…
- Boehringer's obesity drug shows up to 9.8% weight loss in diabetes patients but lags behind competitorsBoehringer Ingelheim presented data at the European Association for the Study of Diabetes (EASD) meeting in Milan, showing its lead obesity candidate achieved up to 9.8% weight reduction in a late-…